CVS Just Made Weight-Loss Drugs Easier to Reach — Here's What the Eli Lilly Deal and $29 Visits Mean for You

The most-searched three letters in health care right now might be "GLP" — and on Wednesday, CVS Health planted a flag squarely in the middle of the weight-loss gold rush. Alongside a blowout second quarter that saw profit nearly triple, the pharmacy giant unveiled a new tie-up with Eli Lilly and a price cut that reads like a shot across the bow of the telehealth industry: virtual weight-loss visits for $29, no membership required.

For the millions of Americans trying to figure out how to get a drug like Zepbound or Wegovy without remortgaging the house, the news matters. Here's what CVS announced, why the stock fell anyway, and what it means for your medicine cabinet.

A blockbuster quarter, powered by Aetna

Start with the numbers, because they were loud. CVS reported net income of roughly $2.98 billion, or $2.31 per share, for the quarter ended June 30 — nearly triple the $1.02 billion it earned a year earlier. Adjusted earnings came in at $2.58 a share, blowing past the $1.85 Wall Street had penciled in, while revenue of $106.10 billion topped the $100.11 billion analysts expected, according to an LSEG survey cited by CNBC.

The engine was Aetna, the insurance arm that has been a migraine for CVS since 2024, when runaway Medicare Advantage costs gutted profits. This quarter, Aetna's medical benefit ratio — the share of premiums paid out in claims — dropped to 87.4% from 89.9% a year earlier. Lower is better, and the improvement helped CVS lift its full-year adjusted earnings guidance to $7.90–$8.10 a share, up from $7.30–$7.50.

CVS also raised its revenue outlook to at least $414 billion and hiked its cash-flow-from-operations forecast to at least $11.5 billion, from at least $9.5 billion. Chairman and CEO David Joyner, who took the top job in 2024, framed it as proof his turnaround is working. It was, by the company's telling, the second straight quarter of raised guidance.

The Eli Lilly deal: Zepbound and Foundayo, on demand

Then came the headline-grabber. CVS said it is teaming up with Eli Lilly so that, starting early in the fourth quarter of 2026, eligible patients can view transparent pricing — including cash-pay options — for two of Lilly's GLP-1 therapies, the injectable Zepbound and the new weight-loss pill Foundayo, right inside the CVS Health app. Per CVS's Aug. 5 release, those patients "will be able to view transparent pricing, including cash-pay options, in the CVS Health app for as early as same-day pickup in one of our 9,000 locations."

That builds on an existing arrangement to carry Novo Nordisk's Wegovy in both oral and injectable forms. Add it up and CVS is positioning its stores as a one-stop shop for every FDA-approved weight-loss drug in the class — whether the patient pays through insurance or out of pocket.

The company also revamped its broader weight-management program. The splashiest move: MinuteClinic virtual weight-loss consultations dropped to $29, from $49, with no membership or recurring monthly fee. Eligible patients connect online with a licensed clinician who can evaluate them and, where appropriate, prescribe GLP-1 therapy, with same-day pickup at a nearby CVS.

Why $29 is a warning shot

To understand why that number matters, look at who CVS is undercutting. The direct-to-consumer weight-loss boom has been built on recurring subscription fees stacked on top of medication costs. Hims & Hers requires an active weight-loss membership that starts at $39 for the first month and auto-renews at $149 a month, billed separately from the drug itself. Ro's "Ro Body" membership follows nearly the same script — $39 to start, then $149 a month on a monthly plan — while Noom Med telehealth runs $69 for the first month and $99 thereafter. Amazon, which launched a GLP-1 program in April 2026, is the closest analog to CVS: it offers on-demand prescription work starting at $29 for a message consultation and $49 for video care, though that lower tier is aimed at renewals for existing prescriptions rather than brand-new ones.

CVS's flat $29 visit with no strings attached is a direct challenge to that whole model. It reframes the first step toward a GLP-1 as a cheap, one-off transaction rather than a monthly toll.

Foundayo, which won a fast FDA approval in April, is Lilly's once-daily pill — a small-molecule drug that's far easier to manufacture and ship than injectable peptides. Its cash price starts around $149 a month for the lowest dose, the same entry point as Novo's Wegovy pill, and both companies set that figure partly to satisfy commitments made to the Trump administration. Per CVS's announcement, eligible commercially insured patients may pay as little as $25 a month with manufacturer coupons, while qualifying uninsured patients can access certain GLP-1s for $149 using manufacturer vouchers.

So why did CVS stock fall?

Here's the twist: despite the blowout, CVS shares fell as much as 10.4% at the New York open on Aug. 5, reversing early premarket gains. The culprit wasn't the quarter — it was the guarded outlook for 2027. On the earnings call, executives warned of expected membership declines at Caremark, the pharmacy-benefit manager, as it shifts to a new pricing model, plus ongoing pressure from the 340B drug-discount program. CFO Brian Newman called a 2027 adjusted EPS floor of "at least $8.44" — matching consensus and implying roughly 13% growth off an adjusted 2026 baseline — "reasonable."

In other words, investors loved the present and worried about the future. Good-but-not-perfect wasn't enough for a stock that had already run up sharply this year.

For patients, the takeaway is simpler and more hopeful. The wall around weight-loss drugs — high prices, confusing access, subscription mazes — is starting to crack. With Medicare now paying, list prices sliding, a cheap pill on the market, and CVS turning 9,000 corner stores into GLP-1 pickup points, getting on one of these medications is becoming less of an ordeal.

The open question is whether the $29 visits and same-day pickup translate into durable loyalty — or whether Amazon, Novo, Lilly's own LillyDirect and a pack of telehealth startups simply match CVS and turn convenience into a price war. Either way, the customer wins. And on Wednesday, CVS made clear it intends to be standing at the center of the biggest consumer-health story of the decade.